Danavorexton Explained

Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist.^[1] It is a small-molecule compound and is administered intravenously. The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial.^[2] As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea.^{[3] [4]} It is related to another orexin receptor agonist, firazorexton (TAK-994), the development of which was discontinued for safety reasons in October 2021.^[5]

See also

• Orexin receptor § Agonists
• List of investigational sleep drugs § Orexin receptor agonists

External links

• Danavorexton - AdisInsight

Notes and References

1. Jacobson LH, Hoyer D, de Lecea L . Hypocretins (orexins): The ultimate translational neuropeptides . J Intern Med . 291. 5. 533–556. January 2022 . 35043499 . 10.1111/joim.13406 . 248119793 .
2. Evans, R., Hazel, J., Faessel, H., Wu, J., Hang, Y., Alexander, R., ... & Hartman, D. (2019). Results of a phase 1, 4-period crossover, placebo-controlled, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925, a novel orexin 2 receptor agonist, in sleep-deprived healthy adults, utilizing modafinil as an active comparator. Sleep Medicine, 64, S106. https://scholar.google.com/scholar?cluster=10933819770107034612
3. Web site: Danavorexton - Takeda . Adis Insight . Springer Nature Switzerland AG . 7 March 2021.
4. Evans R, Tanaka S, Tanaka S, Touno S, Shimizu K, Sakui S, Wu J, Faessel H, Hang Y, Alexander R, Rosen L, Hartman D . 6 . A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes . Sleep Medicine . December 2019 . 64 . S105–S106 . 10.1016/j.sleep.2019.11.290. 213696542 .
5. Web site: Tong A . 6 October 2021 . Endpoints News . Takeda flashes red light on 'breakthrough' narcolepsy drug after PhII trials turned up mysterious safety signal .